Dong Yanqun, Zaorsky Nicholas G, Li Tianyu, Churilla Thomas M, Viterbo Rosalia, Sobczak Mark L, Smaldone Marc C, Chen David Yt, Uzzo Robert G, Hallman Mark A, Horwitz Eric M
Department of Radiation Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Department of Radiation Oncology, Penn State Cancer Institute, Hershey, Pennsylvania, USA.
J Med Imaging Radiat Oncol. 2018 Feb;62(1):116-121. doi: 10.1111/1754-9485.12675. Epub 2017 Oct 13.
To evaluate if interruptions of external beam radiation therapy impact outcomes in men with localized prostate cancer (PCa).
We included men with localized PCa treated with three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT) of escalated dose (≥74 Gy in 1.8 or 2 Gy fractions) between 1992 and 2013 at an NCI-designated cancer centre. Men receiving androgen deprivation therapy were excluded. The non-treatment day ratio (NTDR) was defined as the number of non-treatment days divided by the total elapsed days of therapy. NTDR was analysed for each National Comprehensive Cancer Network (NCCN) risk group.
There were 1728 men included (839 low-risk, 776 intermediate-risk and 113 high-risk), with a median follow up of 53.5 months (range 12-185.8). The median NTDR was 31% (range 23-71%), translating to approximately 2 breaks (each break represents a missed treatment that will be made up) for 8 weeks of RT with 5 treatments per week. The 75 percentile of NTDR was 33%, translating to approximately 4 breaks, which was used as the cutoff for analysis. There were no significant differences in freedom from biochemical failure, freedom from distant metastasis, cancer specific survival, or overall survival for men with NTDR ≥33% compared to NTDR<33% for each risk group. Multivariable analyses including NTDR, age, race, Gleason score, T stage, and PSA were performed using the proportional hazards regression procedure. NTDR≥33% was not significantly associated with increased hazard ratio for outcomes in each risk group compared to NTDR<33%.
Unintentional treatment breaks during dose escalated external beam radiation therapy for PCa did not cause a significant difference in outcomes, although duration of follow up limits the strength of this conclusion.
评估外照射放疗中断是否会影响局限性前列腺癌(PCa)男性患者的治疗结果。
我们纳入了1992年至2013年期间在一家美国国立癌症研究所指定的癌症中心接受三维适形放疗(3D-CRT)或剂量递增(≥74 Gy,每次分割剂量为1.8或2 Gy)的调强放疗(IMRT)的局限性PCa男性患者。接受雄激素剥夺治疗的男性被排除在外。非治疗日比率(NTDR)定义为非治疗天数除以治疗总天数。对每个美国国立综合癌症网络(NCCN)风险组的NTDR进行分析。
共纳入1728名男性(839名低风险、776名中风险和113名高风险),中位随访时间为53.5个月(范围12 - 185.8个月)。NTDR的中位数为31%(范围23% - 71%),这意味着每周进行5次放疗、共8周的疗程中大约有2次中断(每次中断代表一次错过但后续会补上的治疗)。NTDR的第75百分位数为33%,即大约4次中断,以此作为分析的临界值。对于每个风险组,NTDR≥33%的男性与NTDR<33%的男性相比,在无生化复发、无远处转移、癌症特异性生存或总生存方面均无显著差异。使用比例风险回归程序对包括NTDR、年龄、种族、Gleason评分、T分期和前列腺特异性抗原(PSA)在内的多变量进行分析。与NTDR<33%相比,NTDR≥33%在每个风险组中与结局的风险比增加均无显著相关性。
尽管随访时间限制了该结论的力度,但在局限性PCa的剂量递增外照射放疗期间,无意的治疗中断并未导致治疗结果出现显著差异。